DK0954334T3 - Anvendelse af makrofag migration inhibitorisk faktor antagonister til anti-cancer terapi - Google Patents

Anvendelse af makrofag migration inhibitorisk faktor antagonister til anti-cancer terapi

Info

Publication number
DK0954334T3
DK0954334T3 DK97913963T DK97913963T DK0954334T3 DK 0954334 T3 DK0954334 T3 DK 0954334T3 DK 97913963 T DK97913963 T DK 97913963T DK 97913963 T DK97913963 T DK 97913963T DK 0954334 T3 DK0954334 T3 DK 0954334T3
Authority
DK
Denmark
Prior art keywords
mif
inhibitory factor
macrophage migration
migration inhibitory
application
Prior art date
Application number
DK97913963T
Other languages
English (en)
Inventor
Richard J Bucala
Jason A Chesney
Original Assignee
Cytokine Pharmasciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokine Pharmasciences Inc filed Critical Cytokine Pharmasciences Inc
Application granted granted Critical
Publication of DK0954334T3 publication Critical patent/DK0954334T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0337—Animal models for infectious diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Environmental Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK97913963T 1996-10-24 1997-10-24 Anvendelse af makrofag migration inhibitorisk faktor antagonister til anti-cancer terapi DK0954334T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/738,947 US6774227B1 (en) 1993-05-17 1996-10-24 Therapeutic uses of factors which inhibit or neutralize MIF activity
PCT/US1997/019924 WO1998017314A1 (en) 1996-10-24 1997-10-24 Use of macrophage migration inhibitory factor antagonists for anti-cancer therapy

Publications (1)

Publication Number Publication Date
DK0954334T3 true DK0954334T3 (da) 2007-06-11

Family

ID=24970169

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97913963T DK0954334T3 (da) 1996-10-24 1997-10-24 Anvendelse af makrofag migration inhibitorisk faktor antagonister til anti-cancer terapi

Country Status (11)

Country Link
US (3) US6774227B1 (da)
EP (1) EP0954334B1 (da)
JP (2) JP2001502698A (da)
AT (1) ATE354372T1 (da)
AU (1) AU740478B2 (da)
CA (1) CA2267069C (da)
DE (1) DE69737397T2 (da)
DK (1) DK0954334T3 (da)
ES (1) ES2283013T3 (da)
PT (1) PT954334E (da)
WO (1) WO1998017314A1 (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080407A (en) * 1993-05-17 2000-06-27 The Picower Institute For Medical Research Diagnostic assays for MIF
DE19957065B4 (de) 1999-11-26 2005-01-05 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Screening-Verfahren für Arzneistoffe
US6268151B1 (en) * 2000-01-20 2001-07-31 Isis Pharmaceuticals, Inc. Antisense modulation of macrophage migration inhibitory factor expression
US20020114812A1 (en) * 2001-01-12 2002-08-22 Riichiro Abe Methods and compositions for modulating regulation of the cytotoxic lymphocyte response by macrophage migration inhibitory factor
AU2002255961B2 (en) * 2001-03-29 2007-08-23 Baxalta GmbH Methods and compositions for using MHC class II invariant chain polypeptide as a receptor for macrophage migration inhibitory factor
MY140679A (en) 2001-05-24 2010-01-15 Avanir Pharmaceuticals Inhibitors of macrohage migration inhibitory factor and methods for identifying the same
TW200418829A (en) 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
JP2007503388A (ja) 2003-08-22 2007-02-22 アバニール・ファーマシューティカルズ マクロファージ遊走阻止因子の阻害剤としての置換ナフチリジン誘導体、およびヒト疾患の治療におけるそれらの使用
WO2005058304A1 (en) * 2003-12-17 2005-06-30 Cortical Pty Ltd Implantable device containing inhibitor of macrophage migration inhibitory factor
EP1745194A4 (en) * 2004-02-25 2008-02-06 Us Dept Veterans Affairs METHODS FOR DIAGNOSING AND TREATING CANCER OF BLADDER
US20090275521A1 (en) * 2004-12-30 2009-11-05 Katherine Meyer-Siegler Regulation of Microphage Migration Inhibitory Factor (MIF) Activity
WO2006085700A2 (en) * 2005-02-14 2006-08-17 Hvc Stragetic Research Institute, Inc. Pharmaceutical agents for preventing metastasis of cancer
US20060229314A1 (en) 2005-03-24 2006-10-12 Jagadish Sircar Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors
AU2007267593B2 (en) * 2006-05-26 2013-04-04 University Of Louisville Research Foundation, Inc. Macrophage migration inhibitory factor antagonists and methods of using same
WO2009086920A1 (en) * 2008-01-04 2009-07-16 Baxter International Inc. Anti mif antibodies
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
WO2010021693A2 (en) 2008-08-18 2010-02-25 Yale University Mif modulators
DE102008063046A1 (de) 2008-12-23 2010-06-24 Justus-Liebig-Universität Giessen Medizinische Verwendung des ribosomalen Protein S19 (RPS19)
US20100158829A1 (en) * 2008-12-24 2010-06-24 Conopco, Inc., D/B/A Unilever Method and Composition for Color Modulation
EP2480235A4 (en) 2009-09-24 2013-05-08 Univ Louisville Res Found NEW IODO-PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ILLNESSES AND SUFFERING IN CONNECTION WITH THE MACROPHAGE MIGRATION-INHIBITING FACTOR
WO2011146824A1 (en) * 2010-05-20 2011-11-24 University Of Louisville Research Foundation, Inc. Methods and compositions for modulating ocular damage
WO2013010955A1 (en) 2011-07-15 2013-01-24 Morphosys Ag Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
WO2013050453A1 (en) 2011-10-07 2013-04-11 Baxter Healthcare S.A. Oxmif as a diagnostic marker
AU2013202693B2 (en) * 2012-04-16 2015-01-22 Baxalta GmbH Combination Therapy of Anti-MIF Antibodies and Chemotherapeutics
US11397182B2 (en) * 2014-10-07 2022-07-26 Cornell University Methods for prognosing and preventing metastatic liver disease
EP3277718B1 (en) * 2015-03-31 2021-03-24 Baxalta GmbH Dosage regimen for anti-mif antibodies
IL255664A0 (en) 2017-11-14 2017-12-31 Shachar Idit Hematopoietic stem cells with enhanced properties

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4299814A (en) * 1979-05-25 1981-11-10 Monsanto Company Radioimmunoassay of MIF
US4946674A (en) * 1984-10-05 1990-08-07 Bioferon Biochemische Substanzen Gmbh & Co. Process for treatment of rheumatic diseases
US4708937A (en) * 1984-10-15 1987-11-24 Brigham & Women's Hospital Purified migration inhibitory factor also having colony stimulating factor activity
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JPH04504111A (ja) * 1989-03-17 1992-07-23 ジェネティックス・インスティテュート・インコーポレイテッド ヒトマクロファージ遊走阻止因子
GB8915414D0 (en) * 1989-07-05 1989-08-23 Ciba Geigy Novel cytokines
CA2103887C (en) * 1991-12-13 2005-08-30 Gary M. Studnicka Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5585479A (en) * 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA
WO1994026307A1 (en) * 1993-05-17 1994-11-24 The Picower Institute For Medical Research Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity
US6080407A (en) * 1993-05-17 2000-06-27 The Picower Institute For Medical Research Diagnostic assays for MIF
WO1996015242A2 (en) * 1994-11-16 1996-05-23 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods for inhibiting cell proliferation by inhibiting the mitogenic activity of macrophage migration inhibitory factor
US6492428B1 (en) * 2000-07-26 2002-12-10 The Picower Institute For Medical Research Compounds having MIF antagonist activity
US6297253B1 (en) * 1996-10-15 2001-10-02 The Picower Institute For Medical Research Compounds and methods of use to treat infectious diseases
US6011005A (en) * 1997-09-18 2000-01-04 The Picower Institute For Medical Research Prevention of pregnancy miscarriages
JP2003513065A (ja) * 1999-10-29 2003-04-08 ザ・ピコワー・インスティチュート・フォー・メディカル・リサーチ Ｍｉｆアンタゴニスト活性を有する化合物
US6268151B1 (en) * 2000-01-20 2001-07-31 Isis Pharmaceuticals, Inc. Antisense modulation of macrophage migration inhibitory factor expression
US6646493B2 (en) * 2001-08-14 2003-11-11 Micron Technology, Inc. Voltage charge pump with circuit to prevent pass device latch-up

Also Published As

Publication number Publication date
US20080317759A1 (en) 2008-12-25
EP0954334B1 (en) 2007-02-21
JP2001502698A (ja) 2001-02-27
AU5101498A (en) 1998-05-15
AU740478B2 (en) 2001-11-08
US20040156848A1 (en) 2004-08-12
JP2009155335A (ja) 2009-07-16
EP0954334A4 (en) 2002-05-15
DE69737397T2 (de) 2008-02-07
ES2283013T3 (es) 2007-10-16
US6774227B1 (en) 2004-08-10
WO1998017314A1 (en) 1998-04-30
ATE354372T1 (de) 2007-03-15
CA2267069C (en) 2010-12-21
EP0954334A1 (en) 1999-11-10
PT954334E (pt) 2007-05-31
CA2267069A1 (en) 1998-04-30
DE69737397D1 (de) 2007-04-05

Similar Documents

Publication Publication Date Title
DK0954334T3 (da) Anvendelse af makrofag migration inhibitorisk faktor antagonister til anti-cancer terapi
BR9815340A (pt) Utilização de pelo menos um ativador dos receptores de tipo ppar-y.
BRPI0414533A (pt) composto, composição farmacêutica, e, métodos para inibir um hsp90 e para tratar um indivìduo tendo um distúrbio mediado por hsp90
EA200001176A1 (ru) Гетероциклические ингибиторы p38
PT1019040E (pt) Inibicao da actividade de p38-quinase por meio de arilureias
DE69824029D1 (de) Bicyclische kinase inhibitoren
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
DE69836563D1 (de) INHIBIERUNG DER p38 KINASE-AKTIVITÄT DURCH DIE VERWENDUNG VON ARYL- UND HETEROARYLSUBSTITUIERTEN HARNSTOFFEN
ATE424388T1 (de) Mitotische kinesinhemmer
ATE447577T1 (de) Mitotische kinesin-hemmer
BR9814374B1 (pt) "urÉias heterocÍclicas substituÍdas e composiÇÕes compreendendo as mesmas"
DE69328474D1 (de) Verwendung von substituierten Adeninderivaten zur Behandlung von MultipleSklerose
ATE320426T1 (de) Harnstoffderivate und ihre verwendung
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
TR200103336T2 (tr) Amid türevleri.
EA199800391A1 (ru) Ингибирование роста опухоли антисмысловыми олигонуклеотидами к il-8 и il-8 рецептору
UA66865C2 (uk) Інденопіролокарбазоли, фармацевтична композиція, спосіб інгібування кіназної активності та спосіб лікування (варіанти)
EA200001085A1 (ru) 5-аминоиндено [1, 2-с]пиразол-4-оны в качестве противораковых и антипролиферативных агентов
PT1272199E (pt) Terapias de combinacao com actividade de lesao vascular
BR9912279A (pt) Uso de uteroglobina humana recombinante no tratamento de condições inflamatórias e fibróticas
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
UY26426A1 (es) Nuevos compuestos
BR9608245A (pt) Derivados de piperazino como antagonistas de neurocinina
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
ES2189165T3 (es) Nuevos compuestos macrociclicos como inhibidores de metaloproteasa.